TLDR The rash resolved after stopping ponatinib.
A 69-year-old woman with relapsed acute lymphocytic leukemia developed a diffuse, asymptomatic scaly rash 15 days after starting inotuzumab ozogamicin and ponatinib. The rash, characterized by thick plate-like sheets of desquamation, did not improve with prednisone and triamcinolone but resolved upon discontinuation of ponatinib. Histopathology suggested drug-induced acquired ichthyosis, a rare condition associated with medications like ponatinib. Systemic retinoids, specifically oral acitretin, are recommended for refractory cases, although they should be used cautiously due to potential liver enzyme abnormalities.
32 citations
,
September 2015 in “Dermatology” Certain leukemia drugs can cause severe skin reactions that may require stopping treatment.
11 citations
,
July 2022 in “International Journal of Molecular Sciences” Tight junctions help control skin shedding and may be targets for treating certain skin conditions.
April 2023 in “Journal of Investigative Dermatology” New method measures skin cell turnover quickly and effectively, showing turnover slows with age and responds more to treatments in older skin.
6 citations
,
December 2018 in “The American Journal of Dermatopathology” Early shedding of the inner root sheath in noninflamed hair follicles is a relatively specific sign of Central Centrifugal Cicatricial Alopecia.
28 citations
,
June 2007 in “Journal of Cutaneous Pathology” IRS premature desquamation is not unique to CCCA and occurs in various scarring alopecias.
146 citations
,
May 2002 in “The American journal of pathology” Cathepsin L is essential for normal hair growth and development.
